The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line agent in patients with sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hu, Tian, Xu, Zeng, Xian-Tao, Zhang, Yu, Wang, Yi, Wang, Fei, Zhou, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718287/
https://www.ncbi.nlm.nih.gov/pubmed/26765461
http://dx.doi.org/10.1097/MD.0000000000002495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718287/
https://www.ncbi.nlm.nih.gov/pubmed/26765461
http://dx.doi.org/10.1097/MD.0000000000002495

Ejemplares similares